Associate Professor of Pathology, Medicine, and Oncology
M.D., University of Cincinnati College of Medicine, Cincinnati, OH
Cytogenetics, Departments of Pathology and Genetics, University of Pennsylvania School of Medicine, Philladelphia, PA
Dr. Griffin’s research goals are to develop clinically usable tools to collect and analyze family cancer history, and to identify currently unrecognized forms of familial cancer.
She is principal investigator of the Mid-Atlantic Cancer Genetics Network, one of eight sites that make up National Cancer Institute (NCI)-funded initiative called the Cancer Genetics Network (CGN). This national research infrastructure was designed to support collaborative investigations into the inherited susceptibility to cancer. The CGN is intended to enhance and support cancer genetics research that could not be accomplished by single institutions by making available educational, clinical, and research resources. It is specifically intended to facilitate translational research in issues of prevention, treatment, or outcome of cancers related to inherited factors. Now in its sixth year, the CGN has developed pilot studies in several areas, and MACGN is participating in most of these research projects. Dr. Griffin serves as chair of the CGN steering committee and is involved in deriving policies, collaborations, and specific studies with the CGN.
Alterations in specific areas of chromosomes of cancer cells that occur repeatedly indicate areas where genes important in the cancer process reside. Identifying these chromosome changes has led to the identification of many such genes, especially in leukemias. Dr. Griffin continues the search for chromosomal indicators important to genomic changes, with her emphasis on solid tumors. During the past year, she has focused on elucidating some of the many chromosomal abnormalities that characterize pancreatic cancer by mapping breakpoints in pancreas cancer cell lines. Her lab is also developing a unique method for induction of premature chromosome condensation that does not require cells to be growing and dividing, thus eliminating selection of cells that are karyotyped. Successful implementation of this technique would provide new information about the cell-to-cell chromosome variability.
Dr. Griffin’s clinical laboratory in pathology provides cytogenetics services for oncology and other patients. She is interested in recurrent translocations and other abnormalities in hematologic and solid malignancies and in developing assays and applying technologic advances in cytogenetics to provide diagnostic and prognostic information for care of cancer patients. She is expanding the capabilities of the laboratory using automated FISH analysis.
Canto, M.I.; Goggins, M.; Hruban, R.H.; Petersen, G.M.; Giardiello, F.M.; Yeo, C.; Fishman, E.K.; Brune, K.; Axilbund, J.; Griffin, C.; Ali, S.; Richman, J.; Jagannath, S.; Kantsevoy, S.V.; Kalloo, A.N. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-781; quiz 665.
Griffin, C.A.; Burger, P.; Morsberger, L.; Yonescu, R.; Swierczynski, S.; Weingart, J.D.; Murphy, K.M. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology. 2006 Oct;65(10):988-994.
Huff, C.A.; Fuchs, E.J.; Smith, B.D.; Blackford, A.; Garrett-Mayer, E.; Brodsky, R.A.; Flinn, I.W.; Ambinder, R.F.; Borrello, I.M.; Matsui, W.H.; Vogelsang, G.B.; Griffin, C.A.; Luznik, L.; Jones, R.J. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2006 Apr;12(4):414-421.
Jeha, S.; Gaynon, P.S.; Razzouk, B.I.; Franklin, J.; Kadota, R.; Shen, V.; Luchtman-Jones, L.; Rytting, M.; Bomgaars, L.R.; Rheingold, S.; Ritchey, K.; Albano, E.; Arceci, R.J.; Goldman, S.; Griffin, T.; Altman, A.; Gordon, B.; Steinherz, L.; Weitman, S.; Steinherz, P. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006 Apr 20;24(12):1917-1923.
Nayer, H.; Murphy, K.M.; Hawkins, A.L.; Long, P.P.; Gillison, M.; Borowitz, M.; Griffin, C.A. Clonal cytogenetic abnormalities and BCL2 rearrangementin interdigitating dendritic cell sarcoma. Leuk Lymphoma. 2006 Dec;47(12):2651-2654.
Weir, E.G.; Ali Ansari-Lari, M.; Batista, D.A.; Griffin, C.A.; Fuller, S.; Smith, B.D.; Borowitz, M.J. Acute bilineal leukemia: a rare disease with poor outcome. Leukemia. 2007 Nov;21(11):2264-2270.
Loeb, S.; Chan, D.W.; Sokoll, L.; Kan, D.; Maggiore, J.; Mikolajczyk, S.D.; Mondo, D.M.; Griffin, C.R.; Catalona, W.J. Prostate specific antigen assay standardization bias could affect clinical decision making. J Urol. 2008 Nov;180(5):1959-1962; discussion 1962-1953.
Wu, J.M.; Fackler, M.J.; Halushka, M.K.; Molavi, D.W.; Taylor, M.E.; Teo, W.W.; Griffin, C.; Fetting, J.; Davidson, N.E.; De Marzo, A.M.; Hicks, J.L.; Chitale, D.; Ladanyi, M.; Sukumar, S.; Argani, P. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res. 2008 Apr 1;14(7):1938-1946.
Jinawath, N.; Norris-Kirby, A.; Smith, B.D.; Gocke, C.D.; Batista, D.A.; Griffin, C.A.; Murphy, K.M. A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice. J Mol Diagn. 2009 Jul;11(4):359-363.
Ndhlovu, Z.M.; Angenendt, M.; Heckel, D.; Schneck, J.P.; Griffin, D.E.; Oelke, M. Development of an artificial-antigen-presenting-cell-based assay for the detection of low-frequency virus-specific CD8(+) T cells in whole blood, with application for measles virus. Clin Vaccine Immunol. 2009 Jul;16(7):1066-1073.
Campbell, P.J.; Yachida, S.; Mudie, L.J.; Stephens, P.J.; Pleasance, E.D.; Stebbings, L.A.; Morsberger, L.A.; Latimer, C.; McLaren, S.; Lin, M.L.; McBride, D.J.; Varela, I.; Nik-Zainal, S.A.; Leroy, C.; Jia, M.; Menzies, A.; Butler, A.P.; Teague, J.W.; Griffin, C.A.; Burton, J.; Swerdlow, H.; Quail, M.A.; Stratton, M.R.; Iacobuzio-Donahue, C.; Futreal, P.A. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010 Oct 28;467(7319):1109-1113.
Edelstein, D.L.; Axilbund, J.; Baxter, M.; Hylind, L.M.; Romans, K.; Griffin, C.A.; Cruz-Correa, M.; Giardiello, F.M. Rapid Development of Colorectal Neoplasia in Patients With Lynch Syndrome. Clin Gastroenterol Hepatol. 2010 Nov 9.
Mazaheri, P.; Nadkarni, G.; Lowe, E.; Hines, P.; Vuica, M.; Griffin, M.; Resar, L.M. Ghosal hematodiaphyseal dysplasia: a rare cause of a myelophthisic anemia. Pediatr Blood Cancer. 2010 Dec 1;55(6):1187-1190.
Moorman, P.G.; Iversen, E.S.; Marcom, P.K.; Marks, J.R.; Wang, F.; Lee, E.; Ursin, G.; Rebbeck, T.R.; Domchek, S.M.; Arun, B.; Susswein, L.; Isaacs, C.; Garber, J.E.; Visvanathan, K.; Griffin, C.A.; Sutphen, R.; Brzosowicz, J.; Gruber, S.; Finkelstein, D.M.; Schildkraut, J.M. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Res Treat. 2010 Nov;124(2):441-451.
Ndhlovu, Z.M.; Oelke, M.; Schneck, J.P.; Griffin, D.E. Dynamic regulation of functionally distinct virus-specific T cells. Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3669-3674.